Form 4: Odyssey Therapeutics CFO Jason Haas Buys Shares

Chief Financial Officer Jason Haas acquired 1,000 shares of Odyssey Therapeutics, Inc. common stock at $20 per share.

Summary

• Jason Haas, Chief Financial Officer of Odyssey Therapeutics, Inc., purchased 1,000 shares of common stock.
• The transaction occurred on May 8, 2026, at a price of $20.00 per share.
• Following this transaction, the reporting person holds a total of 62,908 shares of common stock directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as insider buying by a CFO typically indicates confidence in the company's financial trajectory.

Positives

• Insider confidence is demonstrated by the CFO's decision to increase his equity stake in the company through an open-market purchase.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

No forward-looking guidance or strategic outlook provided in this filing.

Industry Context

StockSavvy.ai notes that insider buying is generally viewed as a positive signal of management's belief in the company's long-term valuation, particularly in the biotechnology sector where capital allocation is critical.

Comparison to Industry Standards

• Insider purchases by C-suite executives are standard corporate governance signals often interpreted as a sign of alignment with shareholder interests.

Stakeholder Impact

• Shareholders may view the CFO's investment as a sign of internal confidence in the company's future performance.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Odyssey Therapeutics, ODTX, Insider Trading, Form 4, CFO, Equity Purchase